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Purpose
The androgen receptor (AR) plays a central role in prostate cancer. Evidence from several groups
indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor re-
ceptor 2 (HER2) may enhance AR activity in prostate cancer cell lines. This study was designed
to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR
and HER2genes are amplified in prostate cancer tissues. 
Materials and Methods
The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate
cancer samples were investigated by immunohistochemical analysis and chromogenic in situ
hybridization was used to determine whether the EGFRand HER2genes were amplified in these
tissues. 
Results
The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively,
but their expression levels were not significantly associated with clinicopathologic factors. Of the
cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR
protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues
in which EGFR protein was expressed. HER2 expression was detected in only 1 case (1.5%). No
amplification of the EGFRor HER2genes was found in prostate cancer specimens.
Conclusion
This study was limited by small number of subjects, but it can still be inferred that the expression
levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients. The po-
tential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study. 
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Introduction
Androgen receptor (AR) plays a central role in prostate cancer, and an-
drogen-deprivation therapy is therefore the standard initial systemic treat-
ment; however, the tumors eventually recur despite androgen levels
consistent with castration [1]. Such castration-resistant prostate cancers
express high levels of AR mRNA, AR protein, and androgen-regulated
genes, indicating that AR transcriptional activity has been reactivated.
Prostate cancer therefore appears to androgen deprivation through multiple
mechanisms that generate adequate AR activity despite castration-com-
patible levels of circulating androgens [2]. Previous studies have suggested
that the progression to hormone-refractory disease may be associated with
epidermal growth factor receptor (EGFR), epidermal growth factor
(EGF), amphiregulin, and/or transforming growth factor-ʱ (TGF-ʱ). TGF-
ʱ and EGF bind to EGFR, and thus initiate tyrosine kinase activity, which
can leads to the activation of gene expression, cell proliferation, and cell
survival [3]. EGFR and human epidermal growth factor receptor 2
(HER2) also contribute to enhanced AR activity in castration-resistant
prostate cancers. Studies on prostate cancer cell lines and xenograft models
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have found increased EGFR or HER2 expression levels in tumors that
recur after castration, although this result is not consistently reproduced
in patient samples [4,5]. EGF can increase AR transactivation when an-
drogen levels are low, and activation of elements downstream of EGFR
may also enhance AR activity [6].
HER2 has been shown to enhance AR activity and cell growth [7].
Other studies have shown that HER2 can enhance AR stability and that
inhibition of HER2 decreases AR DNA-bindings activity in the presence
of low androgen levels [4,8]. HER2 signaling has also been reported to
negatively regulate AR expression and activity. In a previous study, EGF
was shown to decrease the mRNA expression of ARand androgen-reg-
ulated genes in LNCap cells [9]. Other groups have shown that the binding
of heparin to EGF decreases AR protein expression through activation of
mammalian target of rapamycin and decreased translation AR mRNA
[10,11].
Expression of HER2 and EGFR has been associated with advanced-
stages disease, metastasis, shortened survival, poor response to chemother-
apy, and even the failure of endocrine therapy [12]. Signoretti et al. [13]
demonstrated that an initially minor population of HER2-positive tumor
cells gradually increased, with progression toward androgen-independent
prostate cancer, further justifying the targeting of HER2 in androgen-in-
dependent disease. However, Oxley et al. [14] detected increased HER2
oncogene copy number only rarely in prostate cancers. Therefore, the
HER2 oncogene copy number would not likely useful biomarkers for
identifying patients whose cancer was likely to recur after radical prosta-
tectomy.       
We undertook this study with the following aims: 1) to determine
whether AR, EGFR, and HER2 proteins are expressed in human prostate
cancer; 2) to assess whether the protein expression of AR, EGFR, and
HER2 correlates with clinicopathologic factors in prostate cancer; and 3)
to determine whether the EGFRand HER2genes are amplified in human
prostate cancer.
M ater ials  and  M eth od s
A total of 66 radical prostatectomy samples diagnosed as prostatic ade-
nocarcinoma and 30 transurethral resection samples diagnosed as benign
prostatic hyperplasia (BPH) collected between 2005 and 2009 were ob-
tained from Chung-Ang University Hospital. The samples were fixed
with formalin and embedded in paraffin.
Immunohistochemical analysis and chromogenic in situhybridization
were performed using the tissue microarray (TMA) technique; this
method allows staining of a large number of specimens on 1 slide. TMAs
were prepared manually using a punch biopsy needle (Beecher Instru-
ments Inc., Sun Prairie, WI). To reduce the effects of tumor heterogeneity,
cylindrical core biopsies (2.0 mm in diameter) were extracted from 3 dif-
ferent sites of each tumor, and these cores were arrayed in a recipient
paraffin TMA block.
Tissue sections were mounted on poly-L-lysine coated slides for im-
munohistochemical analysis using the EnVision System Kit (Lab Vision,
Fremont, CA). Anti-AR (1 : 50, Lab Vision), EGFR (1 : 50, Lab Vision),
and HER2 (1 : 50, Lab Vision) primary antibodies were used in this study.
Briefly, the TMA sections were deparaffinized, and hydrated and the en-
dogenous peroxidase activity blocked using standard procedures, and then
subjected to microwave antigen retrieval followed by incubation at 121°C
for 10 minutes. The sections were washed with normal goat serum for 10
minutes, and then incubated with pre-diluted primary antibodies at room
temperature for 60 minutes. The sections were then allowed to react with
peroxidase-conjugated streptoavidin for 45 minutes. The color developed
using diaminobenzidine, and counterstaining performed with hematoxy-
line.
The samples were considered positive for AR expression if more than
10% of the neoplastic cells showed a nuclear staining. EGFR and HER2
expression levels were scored and categorized as 0, 1+, 2+, or 3+, as de-
scribed for the Food and Drug Administration (FDA)-approved Her-
cepTest; expression was considered to be positive at a level of 2+.
For in situ hybridization, the TMA sections were deparaffinized, de-
hydrated, air-dried, and incubated in boiling pre-treatment buffer for 15
minutes using a SPoT-Light FFPE reagent kit (Lab Vision). Enzymatic
digestion was performed with SPoT-Light FFPE digestion enzyme (Lab
Vision) at room temperature for 2-3 minutes. After dehydration, the his-
tological slides were air-dried and the ready to use double-stranded DNA
digoxigenin-labelled EGFR and HER2 probes (Lab Vision) applied. The
samples were denature by incubating the slides, which were covered with
a CISH cover-slip, on a 96°C heat block for 5 minutes, and then hybridized
in a humidity chamber at 37°C overnight. The cover-slips were then re-
moved and the samples stringently washed with 0.5ￗ saline sodium citrate
buffer at 80°C for 5 minutes. Endogenous peroxidase activity and non-
specific staining were blocked with 3% hydrogen peroxide and CAS-
Block, respectively. A mouse antidigoxigenin antibody was added to the
slides and allowed to hybridized with the EGFR and HER2 probes at
room temperature for 45 minutes. The samples were then incubated with
a peroxidase-conjugated goat anti-mouse antibody (Lab Vision) at room
temperature for 45 minutes. A DAB chromogen substrate system was
used to generate a sensitive signal that could be viewed after counterstain-
ing with Mayer’s hematoxylin.
The relationships between the different parameters were determined
by Fisher’s exact test and a Pearson chi-square test using SPSS ver. 12.0
(SPSS Inc., Chicago, IL) statistical software. A p-value less than 0.05 was
considered statistically significant. 
Results
The median age of the prostatic adenocarcinoma patient was 67.2 years
(range, 49 to 80 years). The median pre-operative serum total prostate-
specific antigen (PSA) was 15.26 ng/mL (range, 1.87 to 258.2 ng/mL).
Twelve of 66 patients (18.2%) were classified as stage T2a/T2b, 32
(48.5%) as T2c, 14 (21.2%) as T3a, and 8 (12.1%) as T3b. At the time of
학회지(44-1)_in  12. 3. 27.  오후 2:23  페이지 51Cancer Res Treat. 2012;44(1):50-56
52 CANCER  RESEARCH AND  TREATMENT
Table 1. Expressions of AR and EGFR proteins in BPH and adenocarcinoma
AR EGFR
No. Basal cells Secretory cells Basal cells Secretory cells
BPH 30 0 (0) 25 (83.3) 30 (100) 1 (3.3)
Adenocarcinoma 66 - 39 (59.1) - 27 (40.9)
p-value - 0.021 - 0.0001
Values are presented as number (%). AR, androgen receptor; EGFR, epidermal growth factor receptor; BPH, benign prostatic hyperplasia.
Fig. 1. Expression of androgen receptor. (A) Positive immunoreactivity in benign prostatic glands and stroma (AEC staining, ￗ40). (B) Strong
immunoreactivity in prostatic adenocarcinoma (AEC staining, ￗ400).
A B
Fig. 2. Expression of epidermal growth factor receptor. (A) Strongly positive immunoreactivity in benign prostatic glands and weakly positive
immunoreactivity in prostatic adenocarcinoma (AEC staining, ￗ40). (B) Strong membrane staining in prostatic adenocarcinoma (AEC stain-
ing, ￗ400).
A B
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radical prostatectomy, 3 patients (4.5%) had cancer in lymph nodes and
10 (15.2%) had positive surgical margins.
AR expression was observed in 25 of 30 (83.3%) cases of BPH (Table
1). The staining was observed predominantly in the nuclei of secretory
cells. Benign prostate glands stained homogeneously, whereas both in-
tensity and extent of staining were heterogeneous in prostate cancers (Fig.
1A and B). AR expression was observed in 39 of 66 (59.1%) cases pro-
static adenocarcinoma. AR expression did not correlate significantly with
age, pre-operative PSA level, Gleason score, nodal metastasis, or surgical
margin status. The frequency of AR expression was highest in the group
with the highest pre-operative PSA levels, the highest Gleason scores, and
the presence of nodal metastasis, although these association were not sta-
tistically significant (Table 2).
EGFR expression was observed in the basal cells of all cases and se-
cretory cells of 1 case (3.3%) of BPH (Table 1). EGFR expression was
observed in 27 of 66 (40.9%) cases of prostatic adenocarcinoma (Fig. 2A
and B). The median age of the patients was 67.2 years, when the patient
67 years of age or younger were compared with those over 67 years of
age, the percentage of cancers positive for EGFR expression was found
to be significantly higher (p=0.033) in the younger (≤67 years old) group.
EGFR expression did not correlate significantly with pre-operative PSA
levels, Gleason scores, tumor stage, or surgical margin status. The fre-
quency of EGFR expression was highest in the group with the highest
pre-operative PSA levels, and the highest Gleason scores, the most ad-
Table 2. Correlation of AR and EGFR expression with clinicopathologic factors in 66 prostate adenocarcinomas
AR EGFR
No. (-) (+) (-) (+)
Age (yr)
≤67 29 14 (48.3) 15 (51.7) 13 (44.9) 16 (55.1)
＞67 37 13 (53.1) 24 (64.9) 26 (70.3) 11 (29.7)
p-value NS 0.033
Pre-op PSA (ng/mL)
＜45 2 (40.0) 3 (60.0) 4 (80.0) 1 (20.0)
4-10 31 15 (48.4) 16 (51.6) 17 (54.8) 14 (45.2)
10-20 22 8 (36.4) 14 (63.6) 14 (63.6) 8 (36.4)
＞20 8 2 (25.0) 6 (75.0) 4 (50.0) 4 (50.0)
p-value NS NS
Gleason score
≤6 17 8 (47.0) 9 (53.0) 11 (64.7) 6 (35.3)
7 38 15 (39.5) 23 (60.5) 24 (63.2) 14 (36.8)
≥8 11 4 (36.4) 7 (63.6) 4 (36.4) 7 (63.6)
p-value NS NS
pT stage
T2 44 16 (36.4) 28 (63.6) 27 (61.4) 17 (38.6)
T3 22 11 (50.0) 11 (50.0) 12 (54.5) 10 (45.5)
p-value NS NS
Nodal mets 
Negative 63 26 (41.3) 37 (58.7) 39 (61.9) 24 (38.1)
Positive 3 1 (33.3) 2 (66.7) 0 (0) 3 (100)
p-value NS NS
Surgical margin
Negative 56 21 (37.5) 35 (62.5) 35 (62.5) 21 (37.5)
Positive 10 6 (60.0) 4 (40.0) 4 (40.0) 6 (60.0)
p-value NS NS
Values are presented as number (%). AR, androgen receptor; EGFR, epidermal growth factor receptor; Pre-op PSA, pre-operative serum total
prostate-specific antigen; NS, not significant.
AR
No. (-) (+)
EGFR (-) 39 12 (30.8) 27 (69.2)
(+) 27 15 (55.6) 12 (44.4)
p-value 0.044
Values are presented as number (%). EGFR, epidermal growth factor
receptor; AR, androgen receptor.
Table 3. Correlation of EGFR and AR expression levels in 66
prostate adenocarcinomas
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vanced stages of cancer, the presence of nodal metastasis, and positive
surgical margins, although these association were not statistically signif-
icant.
Of the cases in which tissues were negative for EGFR protein expres-
sion, 69.2% were positive for AR protein expression; however, AR protein
expression was significantly reduced (44.4%, p=0.044) (Table 3) in tissues
in which EGFR protein was expressed.
An HER2 protein expression levels of 2+ was observed in only 1 (Fig.
3A and B). The results of chromogenic in situhybridization indicated no
amplification of either the EGFR gene or HER2 gene in any of the 66
cases (Fig. 4A and B).
Fig. 3. Expression of human epidermal growth factor receptor 2. (A) Negative immunoreactivity in normal prostatic glands and prostatic adeno-
carcinoma (AEC staining, ￗ40). (B) Weakly membrane staining in prostatic adenocarcinoma (AEC staining, ￗ400).
A B
Fig. 4. Epidermal growth factor recptor (EGFR) (A) and human epidermal growth factor recptor 2 (HER2) (B) gene amplification examined by
chromogenicin situhybridization. One or 2 signals are visible in nuclei of adenocarcinoma cells. There is no evidence of gene amplification (CISH
staining, ￗ400).
A B
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Discussion
Prostate cancer is the most frequent cancers in Western countries and
one of the most rapidly increasing malignant diseases in Korean men.
This disease varies greatly over its clinical course, ranging from indolent
to lethal. The investigation of the pathogenesis of prostate cancer is very
challenging, and only a handful of the molecular and genetic factors in-
volved have been identified thus far [15]. However, androgen-related fac-
tors, including androgen metabolism and receptor signaling, correlate
strongly with tumor development and progression [1].
The prostate gland depends on androgen stimulation for its develop-
ment and growth. However, testosterone is not the major androgen re-
sponsible  prostate  growth.  Testosterone  is  converted  into
dihydrotestosterone (DHT) in prostatic stromal and basal cells by the en-
zyme delta 3-ketosteroid 5-alpha-reductase. DHT is primarily responsible
for prostate development and the pathogenesis of BPH [16]. Androgens
significantly alter prostate cancer growth rates, and the progression of
prostate cancer from preclinical to clinically significant forms may result
in part from altered androgen metabolism. Elevated concentrations of
testosterone and its metabolite, DHT may increase prostate cancer risk
over many decades, but results have been inconsistent in this area. Both
endogenous and exogenous factors may affect hormone levels [17]. Stud-
ies of ARgene regulation have implicated the AR itself as a self-regulating
transcription factor that binds the ARgene to increased ARmRNA levels.
Other mechanisms such as increased kinase pathway signaling (HER2,
Ras, or mitogen-activated protein kinase) and altered co-activator/co-re-
pressor ratios, are postulated to increase AR activity and may also lead,
albeit indirectely, to increased AR mRNA levels. Any primary molecular
event that alters AR activity could thus increase ARmRNA levels, sug-
gesting a common final pathway for escape from standard hormone ther-
apy [18]. Despite treatment, prostate cancer eventually recurs as an
androgen- or hormone-independent tumor. The molecular basis for pro-
gression to hormone independent-cancer is poorly understood. One hy-
pothesis is that the function of AR is altered by gene amplification of AR
or a mutation in the hormone-binding domain, the latter occurs in 20-30%
of androgen-independent prostate tumors. A previous study showed that
mutation can alter the specificity of the ligand-binding domain to allow
the mutant AR to bind and respond to other steroid hormones, such as es-
trogen [2]. An alternative model is that AR activation despite clinical an-
drogen deprivation is due to the recruitment of non-steroid receptor signal
transduction pathways [4].
In this study, AR expression was observed in 59.1% and 83.3% of pro-
static adenocarcinoma and BPH cases, respectively. The frequency of AR
expression in adenocarcinoma cases was highest in the group with the
highest pre-operative PSA levels, the highest Gleason scores, and the pres-
ence of nodal metastasis, although these association were not statistically
significant. Together, these results support the hypothesis that increased
levels of AR transcripts may be of particular importance in promoting
tumor cell growth, as indicated in a previous study [2].
EGFR is overexpressed in many cancer, including prostate, kidney, and
urinary bladder carcinomas. The overexpression of EGFR in these carci-
nomas correlates with poor prognosis and decreased survival. Many
agents are used to inhibit EGFR function, including neutralizing mono-
clonal anti-EGFR antibodies, receptor tyrosine kinase inhibitors, and mon-
oclonal antibody-conjugated toxins. Of these antibodies, cetuximab has
received the most attention and has recently been approved by the US
FDA for use in cases of refractory colorectal cancer [19]. Marks et al. [3]
found that EGFRgene expression was detectable in 35% of a large series
of hormone-treated prostate cancers, and that EGFR protein was fre-
quently expressed in tissues from these patients. EGFR over-expression
may be a reasonable target for therapeutic intervention in this otherwise
difficult to treat subset of prostate cancers.
In this study, EGFR protein expression was observed in 40.9% and
3.3% of prostatic adenocarcinoma and BPH cases, respectively. The fre-
quency of EGFR expression was highest in the group with the highest
pre-operative PSA levels, the highest Gleason scores, most advanced
stages of cancer, the presence of nodal metastasis, positive surgical mar-
gins, although these association were not statistically significant. Early
studies using immunohistochemical analysis found EGFR expression in
35.2% of prostate cancers. Of the several variables examined by univariate
analysis, high serum PSA values (≥20), extraprostatic extension, seminal
vesicle invasion, and EGFR expression were significant predictors of bio-
chemical recurrence [20]. These results are consistent with those of several
previous studies describing a correlations between EGFR expression and
prostate cancer progression.
Cai et al. [21] described negative regulation of ARmRNA expression
by EGFR and HER2, which may provide an approach to the suppression
of AR expression in castration-resistant prostate cancer. Previous studies
have indicated that EGF can enhance AR activity and HER2 can enhance
AR activity and responses to low levels of androgen [7]. However, other
studies in LNCap cells found that EGF and heparin binding-EGF decrease
AR expression [10]. In the present study, we observed that AR protein
was expressed in 69.2% of cases in which EGFR protein was not ex-
pressed, but that AR protein expression was significantly reduced when
EGFR protein was expressed. These data suggest that the expression lev-
els of the AR and EGRF proteins are inversely correlated in prostate cancer
patient.
Our results indicated no amplification of the EGFRgene in any of the
66 cases. Changes in EGFRgene copy number are infrequent in prostate
cancers. Most altered tumors have only a low-level EGFRcopy number
increase (3-4 copies), such increase were found in 2.7% of prostate cancer.
Schlomm et al. [22] reported that fluorescence in situhybridization analy-
sis with a dual-labeling probe for centromere 7 and EGFR showed in-
creased EGFR copy numbers in 3.3% of cases. This amplification was
heterogeneous, involving only approximately 30% of the cancer volume.
No EGFRmutations were found in 35 of the cases analyzed. Taken to-
gether, these results showed no specific increase in gene copy number
and no gene amplification.
Previous studies suggested that, statistically, there might be 2 or 3 cases
of abnormal gene copy number in our study. However, no such abnor-
malities were observed in this study. This may be because the relatively
small number of specimens in our study, did not allow detection of sig-
nificant correlation between EGFR protein expression and gene amplifi-
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cation.
The HER2 oncogene encodes a transmembrane tyrosine kinase re-
ceptor with extensive homology to EGFR. HER2 testing is used to predict
the response of breast cancer to trastuzumab [23]. The HER2oncogene
is involved in the biology of many different types of tumors and serves as
a prognostic marker and a therapeutic target in breast cancer. In contrast
to the consensus for breast cancer, studies on HER2overexpression and
gene amplification in prostate cancer have yielded variable results. In a
previous study, a significant increase in copy number was present in 1.75%
of prostate cancers, but chromosome 17 hybridization showed that the in-
crease was the result of polysomy rather than true amplification [14]. In
our study, a HER2 protein expression levels greater than 2+ was observed
in only 1 case; unlike in previous studies, no gene amplification was ob-
served. Minner et al. [24] reported that detectable HER2 immunostaining
in 17.2% of prostate cancers, with the vast majority of cases showing 1+
or 2+ staining. Low-level HER2 overexpression occurs with relevant fre-
quency in prostate cancer and in the absence of gene amplification [24].
These data argue for reconsidering anti-HER2 therapy. 
C onclusion
No clinicopathologic factors was statistically significantly correlated
with AR or EGFR protein expression. AR and EGFR protein expression
levels are inversely correlated in prostate cancer patients. The frequency
of detectable HER2 protein expression was very low, and no amplification
of the EGFR or HER2 genes was observed. Further investigation of
EGFR and HER2 as prognostic factors and therapeutic targets in prostate
cancer is warranted.
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